Skip to main content

Scorpion Therapeutics Appoints Guy Padbury, Ph.D. As Chief Development Officer

BOSTON, MA. — April 8, 2021 — Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the appointment of Guy Padbury, Ph.D. as Chief Development Officer. Dr. Padbury has over 30 years of experience as a scientist and organizational leader in the pharmaceutical and biotechnology industries.

“I am delighted to welcome Dr. Padbury to our growing team of seasoned scientists and entrepreneurs as we advance our Precision Oncology 2.0 pipeline,” said Adam Friedman, M.D., Ph.D., Interim Chief Executive Officer of Scorpion Therapeutics. “Guy brings a proven track record across top-tier drug development organizations and has contributed to more than 40 successful global drug registrations, including small molecules.”

Prior to Scorpion, Dr. Padbury was Senior Vice President of Clinical Development at Merck & Co., where he was responsible for leadership and strategic management in support of drug discovery and development. Previously, Dr. Padbury also served as Vice President and Global Line Head, Pharmacokinetics and Drug Metabolism at Amgen as well as Senior Vice President, Pharmacokinetics, Dynamics and Metabolism at Pfizer. He currently serves on the corporate advisory board for the University of Washington School of Pharmacy, the advisory council for the NIH General Medical Sciences Division, the board of trustees for the Franklin Institute and the advisory board for Illinois Ventures.

“This is an incredibly exciting time to join Scorpion, and I look forward to supporting the company’s mission of making precision oncology the norm rather than the exception for people battling cancer,” said Dr. Padbury.

About Scorpion Therapeutics

Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit

Media Contact

Ravi Moorthy